AVTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AVTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.
The historical data trend for Avalo Therapeutics's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avalo Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Cyclically Adjusted PB Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
Avalo Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted PB Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Avalo Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Avalo Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Avalo Therapeutics's Cyclically Adjusted PB Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Avalo Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:
For example, Avalo Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:
Adj_Book | = | Book Value per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | -131.015 | / | 131.7762 | * | 131.7762 | |
= | -131.015 |
Current CPI (Mar. 2024) = 131.7762.
Avalo Therapeutics Quarterly Data
Book Value per Share | CPI | Adj_Book | |
201406 | 0.000 | 100.560 | 0.000 |
201409 | 0.000 | 100.428 | 0.000 |
201412 | -13,165.500 | 99.070 | -17,511.909 |
201503 | -14,759.000 | 99.621 | -19,522.821 |
201506 | -774.667 | 100.684 | -1,013.893 |
201509 | -10,950.333 | 100.392 | -14,373.660 |
201512 | 4,361.333 | 99.792 | 5,759.155 |
201603 | 2,960.333 | 100.470 | 3,882.750 |
201606 | 1,857.000 | 101.688 | 2,406.461 |
201609 | 186.349 | 101.861 | 241.077 |
201612 | 63.110 | 101.863 | 81.643 |
201703 | -112.698 | 102.862 | -144.377 |
201706 | 639.796 | 103.349 | 815.778 |
201709 | 2,444.199 | 104.136 | 3,092.960 |
201712 | 2,565.378 | 104.011 | 3,250.189 |
201803 | 2,253.254 | 105.290 | 2,820.084 |
201806 | 1,638.448 | 106.317 | 2,030.803 |
201809 | 1,381.586 | 106.507 | 1,709.377 |
201812 | 7.281 | 105.998 | 9.052 |
201903 | 8.049 | 107.251 | 9.890 |
201906 | 6.160 | 108.070 | 7.511 |
201909 | 6.342 | 108.329 | 7.715 |
201912 | 7.308 | 108.420 | 8.882 |
202003 | 20.025 | 108.902 | 24.231 |
202006 | 39.416 | 108.767 | 47.754 |
202009 | 30.056 | 109.815 | 36.067 |
202012 | 19.141 | 109.897 | 22.952 |
202103 | 25.739 | 111.754 | 30.350 |
202106 | 647.510 | 114.631 | 744.355 |
202109 | 1,033.564 | 115.734 | 1,176.826 |
202112 | 589.428 | 117.630 | 660.315 |
202203 | 161.977 | 121.301 | 175.965 |
202206 | -151.850 | 125.017 | -160.060 |
202209 | -51.695 | 125.227 | -54.399 |
202212 | -277.806 | 125.222 | -292.347 |
202303 | -113.945 | 127.348 | -117.907 |
202306 | -119.149 | 128.729 | -121.970 |
202309 | 18.332 | 129.860 | 18.603 |
202312 | 9.110 | 129.419 | 9.276 |
202403 | -131.015 | 131.776 | -131.015 |
Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Avalo Therapeutics (NAS:AVTX) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Thank you for viewing the detailed overview of Avalo Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Armistice Capital Master Fund Ltd. | director, 10 percent owner | C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
Caissa Capital Management Ltd. | 10 percent owner | PALM GROVE HOUSE, WICKHAMS CAY 1 ROAD TOWN, TORTOLA D8 VG1110 |
Christopher Ryan Sullivan | officer: Interim CFO | C/O CERECOR INC., 400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202 |
Garry Arthur Neil | officer: Chief Medical Officer | 555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104 |
Mitchell Chan | director | C/O VIELA BIO, INC., ONE MEDIMMUNE WAY, FIRST FLOOR, AREA TWO, GAITHERSBURG MD 20878 |
Stephen Smolinski | officer: Chief Commercial Officer | C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472 |
Magnus Persson | director | 400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202 |
Joseph M Miller | director | C/O CERECOR INC., 400 EAST PRATT STREET, SUITE 606, BALTIMORE MD 21202 |
Gilla Kaplan | director | C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
June Sherie Almenoff | director | C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019 |
Schond L. Greenway | officer: CFO & Treasurer | C/O CERECOR, INC., 540 GAITHER ROAD, SUITE 400, ROCKVILLE MD 20850 |
H Jeffrey Wilkins | officer: Chief Medical Officer | 600 LEE ROAD, SUITE 100, WAYNE PA 19087 |
Harrell James Archie Jr | officer: Chief Commercial Officer | C/O CERECOR INC., 400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202 |
Illya Keith Maher | director | C/O ARMISTICE CAPITAL, 510 MADISON AVE., 7TH FLOOR, NEW YORK NY 10022 |
Steven Boyd | director, 10 percent owner | 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
From GuruFocus
By Marketwired • 06-26-2023
By Stock market mentor Stock market mentor • 02-02-2023
By GuruFocusNews GuruFocusNews • 06-26-2022
By GuruFocusNews GuruFocusNews • 07-02-2022
By PurpleRose PurpleRose • 08-11-2022
By GlobeNewswire GlobeNewswire • 02-03-2023
By GuruFocusNews GuruFocusNews • 07-06-2022
By GuruFocus Research • 11-09-2023
By Marketwired • 08-03-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.